BR112018010676A2 - polipeptídeo termoestável, uso e meio de cultura - Google Patents
polipeptídeo termoestável, uso e meio de culturaInfo
- Publication number
- BR112018010676A2 BR112018010676A2 BR112018010676-3A BR112018010676A BR112018010676A2 BR 112018010676 A2 BR112018010676 A2 BR 112018010676A2 BR 112018010676 A BR112018010676 A BR 112018010676A BR 112018010676 A2 BR112018010676 A2 BR 112018010676A2
- Authority
- BR
- Brazil
- Prior art keywords
- culture medium
- thermostable polypeptide
- thermostable
- polypeptide
- culture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15196802 | 2015-11-27 | ||
| EP15196802.1 | 2015-11-27 | ||
| PCT/EP2016/073567 WO2017089016A1 (en) | 2015-11-27 | 2016-10-03 | Thermostable fgf2 polypeptide, use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018010676A2 true BR112018010676A2 (pt) | 2019-04-09 |
Family
ID=54754475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018010676-3A BR112018010676A2 (pt) | 2015-11-27 | 2016-10-03 | polipeptídeo termoestável, uso e meio de cultura |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11746135B2 (enExample) |
| EP (1) | EP3380508B1 (enExample) |
| JP (1) | JP7131772B2 (enExample) |
| KR (1) | KR102650035B1 (enExample) |
| CN (1) | CN108779158A (enExample) |
| AU (1) | AU2016359722B2 (enExample) |
| BR (1) | BR112018010676A2 (enExample) |
| CA (1) | CA3006388C (enExample) |
| ES (1) | ES2824479T3 (enExample) |
| LT (1) | LT3380508T (enExample) |
| PL (1) | PL3380508T3 (enExample) |
| SG (1) | SG11201804402WA (enExample) |
| WO (1) | WO2017089016A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112190531B (zh) * | 2019-06-19 | 2022-11-01 | 湖北医药学院 | 抗细胞衰老制剂及其制备方法和应用、细胞及其构建方法 |
| US20210087525A1 (en) * | 2019-09-19 | 2021-03-25 | Northwestern University | Cost effective culture media and protocol for human induced pluripotent stem cells |
| EP4067374A4 (en) * | 2019-11-25 | 2024-03-06 | Korea Institute of Ocean Science and Technology | FGF2 POLYPEPTIDE WITH IMPROVED TEMPERATURE STABILITY AND PROTEASE RESISTANCE AND USE THEREOF |
| KR102428940B1 (ko) * | 2019-11-25 | 2022-08-03 | 한국해양과학기술원 | 온도안정성 및 단백질 분해효소 저항성을 향상시킨 fgf2 폴리펩타이드 및 그 용도 |
| CZ309550B6 (cs) * | 2021-06-15 | 2023-04-05 | Enantis s.r.o | Termostabilní polypeptid na bázi FGF18 a jeho použití |
| GB2616475A (en) * | 2022-03-11 | 2023-09-13 | Multus Biotechnology Ltd | Engineered fibroblast growth factor variants |
| CN120265649A (zh) * | 2022-11-25 | 2025-07-04 | 比特乐健康保健股份公司 | 稳定性提高的fgf-2多肽、制备fgf-2多肽的方法及其用途 |
| CN116041478A (zh) * | 2022-12-19 | 2023-05-02 | 太东(镇江)生物科技有限公司 | 基于大肠杆菌体外纯化系统的人重组热稳定蛋白fgf2制备方法 |
| KR20240173282A (ko) * | 2023-06-02 | 2024-12-11 | (주)피앤피바이오팜 | 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포 유래 엑소좀의 제조방법 |
| KR20240173283A (ko) * | 2023-06-02 | 2024-12-11 | (주)피앤피바이오팜 | 고안정성 활성지속형 염기성 섬유아세포 성장인자 변이체를 이용한 줄기세포의 배양방법 |
| WO2025141173A1 (en) | 2023-12-28 | 2025-07-03 | Meatable B.V. | Methods of increasing differentiation and/or fat accumulation in cells |
| EP4613865A1 (en) | 2024-03-05 | 2025-09-10 | The Cultivated B. GmbH | Animal collagen from non-animal sources |
| WO2025186217A1 (en) | 2024-03-05 | 2025-09-12 | The Cultivated B. Gmbh | Animal collagen from non-animal sources |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU614137B2 (en) | 1988-06-06 | 1991-08-22 | Takeda Chemical Industries Ltd. | Stabilized fgf composition and production thereof |
| US5202311A (en) | 1988-08-19 | 1993-04-13 | Children's Medical Center Corporation | Stabilized fgf composition |
| CA2020654A1 (en) | 1989-07-07 | 1991-01-08 | Yohko Akiyama | Stabilized fgf composition and production thereof |
| US5143829A (en) | 1990-03-29 | 1992-09-01 | California Biotechnology Inc. | High level expression of basic fibroblast growth factor having a homogeneous n-terminus |
| JPH09503661A (ja) | 1993-09-24 | 1997-04-15 | アメリカン シアナミド カンパニー | 繊維芽細胞成長因子の表面ループ構造アナログ |
| AU6339198A (en) * | 1997-02-26 | 1998-09-18 | Ciblex Corporation | Inhibitors of leaderless protein export |
| WO2002017956A2 (en) | 2000-08-31 | 2002-03-07 | Chiron Corporation | Stabilized fgf formulations containing reducing agents |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| EP1444995A1 (en) | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | FGF-2 derived proteins for the preparation of biomaterials or medical devices such as stents |
| US7816140B2 (en) * | 2005-06-14 | 2010-10-19 | The United States Of America As Represented By The Department Of Veterans Affairs | Composition and methods for osteogenic gene therapy |
| US20070212332A1 (en) | 2005-08-11 | 2007-09-13 | Department Of Veterans Affairs | Methods for accelerating bone repair |
| EP2083846B1 (en) * | 2006-09-28 | 2015-07-15 | Hepacore Ltd. | N-terminal fgf variants having increased receptor selectivity and uses thereof |
| US7659379B1 (en) | 2007-05-24 | 2010-02-09 | Florida State University Research Foundation, Inc. | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| EP2333074A1 (en) * | 2009-12-14 | 2011-06-15 | Robert Steinfeld | Substances and methods for the treatment of lysosmal storage diseases |
| EP4202040A1 (en) | 2010-07-01 | 2023-06-28 | Regenerative Research Foundation | Methods for culturing undifferentiated cells using sustained release compositions |
| US9169309B2 (en) | 2011-03-01 | 2015-10-27 | Humanzyme Inc. | Thermostable variants of fibroblast growth factors |
| WO2013082196A1 (en) | 2011-11-28 | 2013-06-06 | The Regents Of The University Of California | bFGF-POLYMER CONJUGATES, METHODS FOR MAKING THE SAME AND APPLICATIONS THEREOF |
| US8772460B2 (en) | 2011-12-16 | 2014-07-08 | Wisconsin Alumni Research Foundation | Thermostable FGF-2 mutant having enhanced stability |
| US9023644B2 (en) | 2011-12-16 | 2015-05-05 | Wisconsin Alumni Research Foundation | FGF having enhanced stability |
| US9474785B2 (en) * | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
| EP2930181B1 (en) * | 2014-04-07 | 2017-10-11 | Miltenyi Biotec GmbH | Fibroblast growth factor muteins with increased activity |
-
2016
- 2016-10-03 LT LTEP16781318.7T patent/LT3380508T/lt unknown
- 2016-10-03 SG SG11201804402WA patent/SG11201804402WA/en unknown
- 2016-10-03 ES ES16781318T patent/ES2824479T3/es active Active
- 2016-10-03 CN CN201680076784.3A patent/CN108779158A/zh active Pending
- 2016-10-03 CA CA3006388A patent/CA3006388C/en active Active
- 2016-10-03 AU AU2016359722A patent/AU2016359722B2/en active Active
- 2016-10-03 US US15/778,743 patent/US11746135B2/en active Active
- 2016-10-03 KR KR1020187018035A patent/KR102650035B1/ko active Active
- 2016-10-03 BR BR112018010676-3A patent/BR112018010676A2/pt active IP Right Grant
- 2016-10-03 WO PCT/EP2016/073567 patent/WO2017089016A1/en not_active Ceased
- 2016-10-03 EP EP16781318.7A patent/EP3380508B1/en active Active
- 2016-10-03 PL PL16781318T patent/PL3380508T3/pl unknown
- 2016-10-03 JP JP2018546742A patent/JP7131772B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PL3380508T3 (pl) | 2021-07-12 |
| WO2017089016A1 (en) | 2017-06-01 |
| JP2019500414A (ja) | 2019-01-10 |
| SG11201804402WA (en) | 2018-06-28 |
| EP3380508B1 (en) | 2020-07-22 |
| CA3006388A1 (en) | 2017-06-01 |
| ES2824479T3 (es) | 2021-05-12 |
| KR102650035B1 (ko) | 2024-03-20 |
| AU2016359722B2 (en) | 2020-09-17 |
| CA3006388C (en) | 2023-05-09 |
| CN108779158A (zh) | 2018-11-09 |
| US11746135B2 (en) | 2023-09-05 |
| US20200270320A1 (en) | 2020-08-27 |
| JP7131772B2 (ja) | 2022-09-06 |
| EP3380508A1 (en) | 2018-10-03 |
| KR20180080335A (ko) | 2018-07-11 |
| LT3380508T (lt) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018010676A2 (pt) | polipeptídeo termoestável, uso e meio de cultura | |
| IL304772A (en) | Antibodies, uses and methods | |
| EP3460042A4 (en) | CELL CULTURE MEDIUM FOR ORGANOID CULTURE, CULTURE METHOD AND ORGANOID | |
| IL264654B1 (en) | Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof | |
| MX374788B (es) | Anticuerpos anti-tim3 y metodos de uso. | |
| MX386587B (es) | ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO. | |
| IL264161A (en) | Tgfb antibodies, methods, and uses | |
| EP3500670A4 (en) | NEW CRISPR SYSTEMS AND ENZYMES | |
| MX372675B (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| KR20180084945A (ko) | 다공성 막 상의 특징부 | |
| BR112016021626A2 (pt) | indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas | |
| MX382518B (es) | Antigenos de citomegalovirus y su uso. | |
| CL2016001102A1 (es) | Anticuerpos anti-claudina novedosos y métodos de uso. | |
| EP3448982A4 (en) | CELL CULTURE MEDIUM | |
| BR112017025828A2 (pt) | dispositivo de nó hospedeiro e métodos de uso com o mesmo. | |
| CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
| IL247458A0 (en) | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio | |
| CL2020000951A1 (es) | Célula. | |
| CL2018001139A1 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos. | |
| BR112018005411A2 (pt) | sabor derivado de parede celular de levedura. | |
| CL2018002543A1 (es) | Anticuerpos gitr, metodos y usos. | |
| FI3265123T3 (fi) | Vasta-aineita, käyttöjä & menetelmiä | |
| EP3420072A4 (en) | CELL CULTURE MEDIUM | |
| FI20165526A7 (fi) | Fruktaanihydrolaasiaktiivisuutta omaava entsyymi | |
| CL2016001921A1 (es) | Proteínas inmovilizadas y uso de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: MASARYKOVA UNIVERZITA (CZ) ; ENANTIS S.R.O. (CZ) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/10/2016, OBSERVADAS AS CONDICOES LEGAIS |